DCGI orders suspension of Serum's India trials of AstraZeneca's COVID-19 vaccine - ANI

FILE PHOTO: A man walks past a signpost of India's Serum Institute, the world's largest maker of vaccines, which is developing a vaccine against the coronavirus disease (COVID-19) at its laboratory in Pune, India, May 18, 2020. REUTERS/Euan Rocha/File Photo

(Reuters) - India's drug regulator has asked Serum Institute of India to suspend recruitment in its clinical trials of AstraZeneca Plc's potential COVID-19 vaccine in the country until further orders, Reuters partner ANI reported on Friday.

V.G. Somani, the drugs controller general of India, has also asked for increased safety monitoring of those already vaccinated with the experimental vaccine, ANI reported https://www.aninews.in/news/national/general-news/dcgi-directs-serum-institute-to-suspend-any-new-recruitment-in-phase-2-3-covid-19-vaccine-clinical-trials20200912000916, citing an order issued by the regulator.